Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer.

Gynecologic oncology

Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial.

Cardiovascular revascularization medicine : including molecular interventions

Glucagon-like peptide-1 receptor agonists (GLP1RA) in the management of mitochondrial diabetes in an adolescent: A Case Report.

Hormone research in paediatrics

GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.

Annals of medicine

GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling.

Science progress

Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition : A Systematic Review.

Annals of internal medicine

Glucagon-Like Peptide-1 Receptor Agonists: Their Therapeutic Potential in Cystic Fibrosis.

Advances in therapy

Outcomes of Body Contouring Surgery After Bariatric Surgery vs. GLP-1 Receptor Agonist-Induced Weight Loss: A Propensity Score Matched Analysis.

Aesthetic plastic surgery

@TheLongInvest For now, it's $HIMS. But I suspect it'll be $AVCT #AVCT in the not-too-distant future. The large majority of US retail associate #peptides with the GLP-1 mimetics (semaglutide, tirzepatide) and bioregulatory / research peptides (e.g. BPC-157; TB-500; GHK-Cu, etc.). But the

🚨 $HIMS +46% in 1 week as FDA schedules peptide compounding review (July 23–24) The FDA will evaluate 7 peptides for compounding eligibility: → BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon ✅Hims & Hers CMO called it an “avenue toward trusted channels” This is https://t.co/yKIFM6lEZh

BREAKING NEWS: Peptides are coming In July, the FDA is reviewing BPC-157, TB-500, Semax, Epitalon and more. The meeting will be open to the public. The peptide era begins. https://t.co/hGR3ZPfhnU

This week the FDA quietly admitted the research peptide community was right ALL ALONG!!!!! For 3 years they called BPC-157 "high-risk" and blocked access. No evidence. No bodies. Just bureaucratic theater. Now they're walking it back. Here's what it actually means 🧵

On July 23–24, 2026, an FDA advisory committee will evaluate whether multiple peptide substances—BPC-157, KPV, TB-500, MOTS-C, emideltide (DSIP), semax, and epitalon—should be added to the 503A compounding list, including review of proposed uses and sponsor presentations.

🚨 $KITL BULLISH ALERT: FDA Peptide Reversal = Massive Catalyst for the OTC Pioneer! With RFK Jr. at HHS and the FDA now actively weighing the lift on restrictions for ~14 key peptides (BPC-157, TB-500, CJC-1295, GHK-Cu, and more), the gray-market peptide era is ending — and

• HHS Secretary Kennedy just announced the FDA is removing 12 key peptides from Category 2 restrictions starting with BPC-157 and others moving to full scientific review. • $HIMS is not a GLP-1 only company. The entire peptide industry stands ready to boom as regulated access https://t.co/3HzcTJWfS0 https://t.co/9UySm2FWBU

Common GLP 1 agents: •Semaglutide (Ozempic, Wegovy) •Liraglutide (Victoza, Saxenda) •Dulaglutide (Trulicity) •Exenatide (Byetta, Bydureon) •Tirzepatide (Mounjaro, Zepbound), a dual GLP-1 and GIP agonist with greater potency